Standout Papers

Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight... 1995 2026 2005 2015 3.0k
  1. Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects (1995)
    Margherita Maffei, Jeffrey L. Halaas et al. Nature Medicine
  2. Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Association with Insulin Resistance and Hyperinsulinemia (2001)
    Christian Weyer, Tohru Funahashi et al. The Journal of Clinical Endocrinology & Metabolism
  3. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus (1999)
    Christian Weyer, Clifton Bogardus et al. Journal of Clinical Investigation
  4. Impaired Fasting Glucose and Impaired Glucose Tolerance (2007)
    David M. Nathan, Mayer B. Davidson et al. Diabetes Care
  5. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes (2020)
    Christopher P. Cannon, Richard E. Pratley et al. New England Journal of Medicine
  6. Diabetes in Older Adults (2012)
    M. Sue Kirkman, Vanessa Jones Briscoe et al. Diabetes Care
  7. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials (2021)
    Naveed Sattar, Matthew M.Y. Lee et al. The Lancet Diabetes & Endocrinology
  8. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes (2020)
    Darren K. McGuire, Weichung Shih et al. JAMA Cardiology
  9. Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts Type II diabetes independent of insulin resistance (2000)
    C. Weyer, James E. Foley et al. Diabetologia
  10. High Alanine Aminotransferase Is Associated With Decreased Hepatic Insulin Sensitivity and Predicts the Development of Type 2 Diabetes (2002)
    Barbora Vozarova, Norbert Stefan et al. Diabetes
  11. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial (2018)
    Richard E. Pratley, Vanita R. Aroda et al. The Lancet Diabetes & Endocrinology
  12. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023 (2022)
    Nuha A. ElSayed, Grazia Aleppo et al. Diabetes Care
  13. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial (2010)
    Richard E. Pratley, Michael A. Nauck et al. The Lancet
  14. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes (2021)
    Hertzel C. Gerstein, Naveed Sattar et al. New England Journal of Medicine
  15. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes (2017)
    Steven P. Marso, Darren K. McGuire et al. New England Journal of Medicine
  16. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial (2019)
    Richard E. Pratley, Aslam Amod et al. The Lancet
  17. 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2022)
    Nuha A. ElSayed, Grazia Aleppo et al. Diabetes Care
  18. Diabetes in Older Adults: A Consensus Report (2012)
    M. Sue Kirkman, Vanessa Jones Briscoe et al. Journal of the American Geriatrics Society
  19. GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials (2020)
    Matthew P. Gilbert, Richard E. Pratley Frontiers in Endocrinology
  20. 7. Diabetes Technology: Standards of Care in Diabetes—2023 (2022)
    Nuha A. ElSayed, Grazia Aleppo et al. Diabetes Care
  21. 15. Management of Diabetes in Pregnancy:Standards of Care in Diabetes—2023 (2022)
    Nuha A. ElSayed, Grazia Aleppo et al. Diabetes Care
  22. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2023 (2022)
    Nuha A. ElSayed, Grazia Aleppo et al. Diabetes Care
  23. 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes—2023 (2022)
    Nuha A. ElSayed, Grazia Aleppo et al. Diabetes Care
  24. 13. Older Adults: Standards of Care in Diabetes—2023 (2022)
    Nuha A. ElSayed, Grazia Aleppo et al. Diabetes Care
  25. 14. Children and Adolescents: Standards of Care in Diabetes—2023 (2022)
    Nuha A. ElSayed, Grazia Aleppo et al. Diabetes Care
  26. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2024)
    Sunil V. Badve, Matthew M.Y. Lee et al. The Lancet Diabetes & Endocrinology

Immediate Impact

20 from Science/Nature 149 standout
Sub-graph 1 of 13

Citing Papers

Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
2025 Standout
Diabetes mellitus—Progress and opportunities in the evolving epidemic
2024 Standout
57 intermediate papers

Works of Richard E. Pratley being referenced

Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial
2021
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
2021 Standout
and 30 more

Author Peers

Author Last Decade Papers Cites
Richard E. Pratley 16147 8472 9836 392 34.6k
Richard N. Bergman 15615 10689 12034 622 41.1k
Steven E. Kahn 20367 12423 13019 467 45.2k
Ralph A. DeFronzo 18905 13264 11642 282 37.6k
Matti Uusitupa 13017 6664 11559 477 36.3k
Michael Stümvoll 7094 9549 11582 574 31.0k
Samuel Klein 9938 11621 22926 380 46.9k
John Wilding 19105 9212 7812 439 33.8k
Bo Åhrén 15941 9921 7467 717 32.4k
K. G. M. M. Alberti 16910 5056 9506 441 37.2k
Peter Arner 8412 10658 20834 573 43.0k

All Works

Loading papers...

Rankless by CCL
2026